// App-Quantinova.ai

2295 : Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel CELMoD Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma

Researchers

Presenter

  • Lilly Wong

Principal Investigators

  • Mara Dolores Jimnez Nuez

  • Daniel Bauer

  • Paul G. Richardson

  • Nizar Bahlis

  • Annette J. Vangsted

  • Karthik Ramasamy

  • Suzanne Trudel

  • Joaqun Martnez-Lopez

  • Mara-Victoria Mateos

  • Paula Rodriguez-Otero

  • Sagar Lonial

  • Rakesh Popat

  • Albert Oriol

  • Chatchada Karanes

  • Robert Z. Orlowski

  • Jesus G. Berdeja

  • Michael Pourdehnad

  • Daniel W. Pierce

Medical Centers

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Celgene Research SLU, A Bristol-Myers Squibb Company, Seville, CA, Spain

  • Dana-Farber Cancer Institute, Boston, MA

  • Charbonneau Cancer Institute at the University of Calgary, Calgary, AB, Canada

  • Department of Hematology, Rigshospitalet, Copenhagen, Denmark

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Department of Hematology, Hospital 12 de Octubre, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid, Spain

  • University Hospital of Salamanca, Salamanca, Spain

  • Clinica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain

  • Winship Cancer Institute of Emory University School of Medicine, Atlanta, GA

  • NIHR Clinical Research Facility, University College London Hospitals, London, United Kingdom

  • Institut d’Investigació Contra la Leucèmia Josep Carreras and Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain

  • The Judy and Bernard Briskin Center for Clinical Research, City of Hope, Duarte, CA

  • Dept of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX

  • Sarah Cannon Research Institute, Nashville, TN

Locations

  • United States

  • Spain

  • Canada

  • Denmark

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacodynamics

  • Adaptive

  • Dose Escalation

Phase

  • NA

Study Id's

  • NCT03374085

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved